Neurotech Insights
February 28, 2007
Inside this Issue: Obsessive Compulsive Disorder
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: OCD
Featured Company: New River Pharmaceuticals (NRPH)
Subscribe now to access over 30 articles in this issue on developments in neurotech, including drugs, devices and diagnostics.
Market Highlights: Cortex Bounces Back; NeuroChem's Moment of Truth
Cortex (COR) bounced back over 50% after alleviating toxicity concerns related to their ADHD lead. Developments in obesity dominated the news this month with announcements from Metabolic (ASX:MBP), GlaxoSmithKline (GSK), AstraZeneca (AZN), and Arena (ARNA). Neurochem (NRMX) announced completion of enrollment in their US Phase III Alzheimer’s trial and continued indications of safety in the European trial…
Obsessive Compulsive Disorder: Symptoms and Treatments
OCD is a type of anxiety disorder. Apart from OCD, anxiety disorders include phobic disorders, phobias, panic disorder, panic attacks, post-traumatic stress disorder and generalized anxiety disorers. OCD is characterized by obsessions, or recurrent intrusive ideas, images, and urges, and compulsions, or impulses to lessen the unease cause by such obsessions by performing repetitive behaviors or mental acts. The OCD patient does not derive any pleasure or satisfaction from their acts like compulsive eaters, drinkers or gamblers do. In OCD the whole purpose of compulsive behavior is to control and manage the anxiety and stress resulting from the unwanted obsessions...
Neurotech a Major Beneficiary of $45 Million in Awards from California Stem Cell Initiative
More than two years after voters approved a $3 billion program to fund stem cell research in California, the state has approved the first grants focused solely on human embryonic stem cell research. About one quarter of the initial grants are focused specifically on advancing treatments for the brain and nervous system…
New River Pharmaceuticals Reaches the Top of a Steep Climb with $2.6 Billion Acquisition by Shire
New River Pharmaceuticals (NRPH) is a specialty pharma company based in Radford, VA. It went public in the summer of 2004 selling $4.2 million shares at $8.00 a share. WR Hambrecht was the lead underwriter. Since then its stock has gone up nearly 1,500%. This month the company received FDA approval for their new treatment for ADHD, Vyvanse (previously NRP104). Three days before the approval, the marketing partner for the drug, Shire Pharmaceuticals Group plc (SHPGY) announced plans to acquire the company for $64 per New River share, or approximately $2.6 billion cash...
Companies covered in this issue include: Amarin, Amicus, BioBehavioral Diagnostics, CeNes Pharma, Cortex, Critical Therapeutics, Cyberkinetics Neurotechnology Systems, Debiopharm, elbion, Eli Lilly, Elixir, GlaxoSmithKline, Greatbatch, Innovative Metabolics, Intellect Neurosciences, Medtronic, Merck, Metabolic Pharma, Mind Care Centres, Neurochem, Neurogesx, Neurologica, New River Pharma, NovoNordisk, Palatin, Siena, Shire, Stem Cell Sciences, St. Jude Medical, Tikvah, Therapade, Wyeth, Xenoport.
Subscribe now for these articles and much much more... |
|
